

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Brad St. Croix, et al.) Confirmation No. 7620
Serial No. 10/519,805) Group Art Unit: 1643
Filed: December 13, 2005) Examiner: M. Natarajan
For: Secreted and Cytoplasmic Tumor) Atty Docket: 001107.00527
Endothelial Markers)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In response to the Office Action mailed July 25, 2007, applicants elect Group XII directed to claims 23-24. This election is made with traverse with regard to the restriction of Group XII from Group III, directed to claim 8.

The two groups of claims differ in the sample tested (a population of cells versus a body fluid), the reagent (one or more antibodies versus a molecule comprising an antibody variable region), and the preamble (method of identifying endothelial cells versus method of screening for neoangiogenesis). It is respectfully submitted that these differences are not so great that they would present an undue search burden if the groups were rejoined.

Applicants elect as a species the protein known as secreted protein, acidic, cysteine-rich (osteonectin). Each of claims 23, 24, and 8 read on this species.

Please extend the time for responding to January 25, 2008, *i.e.*, for five months. Please charge the fee of \$2,230.00 to our deposit account number 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By:



Sarah A. Kagan
Registration No. 32,141

Date: January 25, 2008

Banner & Witcoff, Ltd.
Customer Number: 22907